会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • Preventives/remedies for inflammatory airway diseases
    • 炎症性气道疾病的预防/补救措施
    • US07214672B2
    • 2007-05-08
    • US10451061
    • 2001-12-21
    • Teruo KomotoHiroyuki MizunoYoshinori TakahashiKoichi TakahashiSusumo Sato
    • Teruo KomotoHiroyuki MizunoYoshinori TakahashiKoichi TakahashiSusumo Sato
    • A61K31/56A61K31/58
    • C07J5/00A61K31/57A61K31/573C07J7/00
    • A preventive and/or therapeutic agent for inflammatory respiratory tract diseases containing, as an active ingredient, a steroid derivative represented by the following formula (1): (wherein R represents a hydrogen atom, a halogen atom, a hydroxy group, or —OCOR1 (wherein R1 represents a linear or branched alkyl group which may be substituted by a halogen atom or a cycloalkyl group; a cycloalkyl group; or an aryl group)). These compounds can continuously suppress respiratory tract inflammation and respiratory tract hyperreaction and show a high site selectivity and little systemic effect when administered directly to the respiratory tract. By virtue of these characteristics, these compounds are remarkably useful in clinical medicine as highly safe preventive and/or therapeutic agents for inflammatory respiratory tract diseases which can be administered for a long period of time.
    • 一种炎性呼吸道疾病的预防和/或治疗剂,含有下式(1)表示的类固醇衍生物作为活性成分:(式中,R表示氢原子,卤素原子,羟基或-OCOR (其中R 1表示可被卤素原子或环烷基取代的直链或支链烷基;环烷基;或芳基))。 这些化合物可以连续抑制呼吸道炎症和呼吸道高反应,并且当直接施用于呼吸道时显示出高的选择性和很小的全身效应。 由于这些特征,这些化合物在临床医学中非常有用,作为可长期施用的炎症性呼吸道疾病的高度安全的预防和/或治疗剂。
    • 8. 发明授权
    • Pyrazolothiazole compound
    • 吡唑并噻唑化合物
    • US08530504B2
    • 2013-09-10
    • US12900026
    • 2010-10-07
    • Kogyoku ShinTaro TerauchiYoshinori TakahashiMinako HashizumeKunitoshi TakedaKodo ShikataAkira Inomata
    • Kogyoku ShinTaro TerauchiYoshinori TakahashiMinako HashizumeKunitoshi TakedaKodo ShikataAkira Inomata
    • A61K31/429A61P25/24
    • C07D513/04
    • A compound represented by the formula (I) or pharmacologically acceptable salt thereof exhibits an excellent CRF receptor antagonism wherein X is a nitrogen atom or CH; R1 is -A11-A12; A11 is a single bond or a C1-6 alkylene group; A12 is a hydrogen atom, a C1-6 alkyl group or a C3-6 cycloalkyl group, etc.; R2 is -A21-A22; A21 is a single bond or a C1-6 alkylene group; A22 is a hydrogen atom, a C1-6 alkyl group, a C3-6 cycloalkyl group, a non-aromatic heterocyclic group, or a heteroaryl group, etc.; R3 is a C1-6 alkyl group, a C3-6 cycloalkyl group, a C1-6 alkoxy group, a C3-6 cycloalkoxy C1-6 alkyl group, di-C1-6 alkyl amino group, a halogen atom, a cyano group, a formyl group, or a carboxyl group, etc; R4 is a hydrogen atom or a C1-6 alkoxy group; R5 is a halogen atom, a C1-6 alkyl group, or a C1-6 alkoxy group; R6 is a hydrogen atom, a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkylthio group, or a C1-6 alkyl sulfinyl group etc.; and R7 is a C1-6 alkyl group, a C1-6 alkoxy group, or a C1-6 alkylthio group.
    • 由式(I)表示的化合物或其药理学上可接受的盐表现出优异的CRF受体拮抗作用,其中X为氮原子或CH; R1为-A11-A12; A11是单键或C1-6亚烷基; A12是氢原子,C1-6烷基或C3-6环烷基等; R2为-A21-A22; A21是单键或C1-6亚烷基; A22为氢原子,C1-6烷基,C3-6环烷基,非芳族杂环基或杂芳基等; R3是C1-6烷基,C3-6环烷基,C1-6烷氧基,C3-6环烷氧基C1-6烷基,二C1-6烷基氨基,卤素原子,氰基 ,甲酰基或羧基等; R4是氢原子或C1-6烷氧基; R5是卤素原子,C1-6烷基或C1-6烷氧基; R6是氢原子,C1-6烷基,C1-6烷氧基,C1-6烷硫基或C1-6烷基亚磺酰基等; 且R 7为C 1-6烷基,C 1-6烷氧基或C 1-6烷硫基。